retatrutide triple agonist glp-1 gip glucagon phase 2 obesity Retatrutide, the triple-G (GLP-1, GIP, and receptor) caused patients with and knee osteoarthritis to lose an average of 23.7% of body weight after 68 weeks, according to the results Retatrutide is a next-generation triple-pathway

In vitro and preclinical studies highlight the complexity of GLP-1 signaling in cancer biology

The role of obesity and bariatric surgery-induced weight loss in breast cancer

Because alcohol is already a stomach irritant, its best to avoid it while your body gets used to your semaglutide

The Proof Is in the Progress The MindBody GLP-1 System offers a natural approach to supporting weight loss and enhancing overall well-being by leveraging the power of GLP-1

Amber Wheeler, Endocrinologist and Advisor at hey freya womens health, sat down with us to discuss the effectiveness and safety of this new supplement

The weight loss timeline followed a predictable arc across all dose groups